Rabia Agca

TL;DR: The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased, which underscores the need for CVDrisk management in these patients.

TL;DR: Patients, general practitioners, cardiologists, internists and rheumatologists need to be aware of the substantially increased CV risk in IJD and should make a combined effort to timely initiate CV risk management in accordance with prevailing guidelines together with optimal control of rheumatic disease activity.

TL;DR: NIK+EC associate with chronic inflammation in advanced lesions and are linked to markers of local inflammation, lipid content, unstable plaque phenotype and development of MI, therefore, targeting noncanonical NF-κB signaling may hold therapeutic potential for patients with atherosclerosis and cardiovascular disease.

TL;DR: The incidence rate of CV events in established RA was more than double that of the general population, and this risk remained after adjustment for traditional CV risk factors, suggesting that systemic inflammation is an independent contributor to CV risk.

TL;DR: A functional effect of a promoter single-nucleotide polymorphism (SNP) in IL32 is shown on lipid profiles in RA patients and individuals, suggesting a possible protective role of this SNP against CVD.